Mirae Asset Global Investments Co. Ltd. Has $5.98 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Mirae Asset Global Investments Co. Ltd. raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 17.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 217,394 shares of the company’s stock after purchasing an additional 31,536 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.23% of Intellia Therapeutics worth $5,981,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Los Angeles Capital Management LLC raised its stake in shares of Intellia Therapeutics by 3.7% in the 4th quarter. Los Angeles Capital Management LLC now owns 11,695 shares of the company’s stock valued at $357,000 after purchasing an additional 422 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Intellia Therapeutics by 7.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 8,144 shares of the company’s stock valued at $248,000 after acquiring an additional 582 shares during the last quarter. Axxcess Wealth Management LLC increased its position in shares of Intellia Therapeutics by 4.0% in the fourth quarter. Axxcess Wealth Management LLC now owns 15,592 shares of the company’s stock valued at $475,000 after acquiring an additional 594 shares during the last quarter. Interchange Capital Partners LLC increased its position in shares of Intellia Therapeutics by 6.3% in the fourth quarter. Interchange Capital Partners LLC now owns 10,239 shares of the company’s stock valued at $311,000 after acquiring an additional 605 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Intellia Therapeutics by 2.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,385 shares of the company’s stock valued at $713,000 after acquiring an additional 647 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Up 4.0 %

Shares of NASDAQ:NTLA opened at $23.15 on Thursday. Intellia Therapeutics, Inc. has a 12-month low of $19.37 and a 12-month high of $46.50. The stock has a market cap of $2.23 billion, a PE ratio of -4.32 and a beta of 1.82. The business has a 50 day moving average of $23.97 and a 200-day moving average of $25.85.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. The firm had revenue of $28.94 million for the quarter, compared to the consensus estimate of $15.60 million. Equities research analysts expect that Intellia Therapeutics, Inc. will post -4.98 earnings per share for the current year.

Analyst Ratings Changes

NTLA has been the topic of a number of recent research reports. Wedbush reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. BMO Capital Markets lifted their target price on Intellia Therapeutics from $62.00 to $70.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Citigroup lowered their target price on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Friday, May 10th. Truist Financial reiterated a “buy” rating and set a $120.00 price target on shares of Intellia Therapeutics in a report on Monday, June 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $69.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.